1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

04 Mar 2024
Admin
News Article

Jacobio Pharma Gets Approval for Jab-30300

Jacobio Pharma receives IND approval for P53 Y220C activator JAB-30300 in US

Overview

Jacobio Pharma, a clinical-stage oncology company committed to developing and providing new and innovative products and solutions to improve people's health, announced it has received IND (Investigational New Drug) approval of its self-developed drug JAB-30300 (P53 Y220C activator) from the US FDA.

Future plans

Jacobio plans to initiate a phase I/IIa advanced solid tumors clinical trial in the US, to evaluate safety and efficacy of JAB-30300. Jacobio also plans to submit IND in China, and will conduct clinical studies once receives the IND approval.

About P53

P53 is the single most frequently altered gene in human cancers, with mutations being present in approximately 50% of all invasive tumors.
JAB-30300 is an orally bioavailable small molecule activator for the treatment of patients with solid tumors harboring P53 Y220C mutation.
Studies shows that, JAB-30300 has shown very high binding affinity to P53 Y220C mutant proteins.
Tumor regression was achieved in multiple cancer models covering various tumor types, such as gastric cancer, ovarian cancer, breast cancer and lung cancer.
The synergistic effect was found when combined with chemo or oncogenic protein inhibitors which indicates a widely combo potential of JAB-30300.
There is only one P53 Y220C activator program in the phase I clinical stage globally.
JAB-30300 is expected to be one of the first P53 Y220C activator to be approved.

Jacobio Pharma’s Aim

Jacobio Pharma’s pipeline revolves around novel molecular targets on six major signalling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB and MYC.
We aim for our key projects to be among the top three in the world. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners.
Jacobio has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our iADC Platform.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!